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CARP-1 Functional Mimetics Are a Novel Class of Small
Molecule Inhibitors of Malignant Pleural Mesothelioma
Cells
Shazia Jamal1,3.¤b, Vino T. Cheriyan1,3., Magesh Muthu1,3, Sara Munie1,3, Edi Levi1,4,
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Abstract
Malignant pleural mesothelioma (MPM) is an asbestos-related thoracic malignancy that is characterized by late metastases,
and resistance to therapeutic modalities. The toxic side-effects of MPM therapies often limit their clinical effectiveness, thus
necessitating development of new agents to effectively treat and manage this disease in clinic. CARP-1 functional mimetics
(CFMs) are a novel class of compounds that inhibit growth of diverse cancer cell types. Here we investigated MPM cell
growth suppression by the CFMs and the molecular mechanisms involved. CFM-1, -4, and -5 inhibited MPM cell growth, in
vitro, in part by stimulating apoptosis. Apoptosis by CFM-4 involved activation of pro-apoptotic stress-activated protein
kinases (SAPKs) p38 and JNK, elevated CARP-1 expression, cleavage of PARP1, and loss of the oncogene c-myc as well as
mitotic cyclin B1. Treatments of MPM cells with CFM-4 resulted in depletion of NF-kB signaling inhibitor ABIN1 and
Inhibitory kB (IkB)a and b, while increasing expression of pro-apoptotic death receptor (DR) 4 protein. CFM-4 enhanced
expression of serine-phosphorylated podoplanin and cleavage of vimetin. CFMs also attenuated biological properties of the
MPM cells by blocking their abilities to migrate, form colonies in suspension, and invade through the matrix-coated
membranes. Both podoplanin and vimentin regulate processes of cell motility and invasion, and their expression often
correlates with metastatic disease, and poor prognosis. The fact that phosphorylation of serines in the cytoplasmic domain
of podoplanin interferes with processes of cellular motility, CFM-4-dependent elevated phosphorylated podoplanin and
cleavage of vimentin underscore a metastasis inhibitory property of these compounds, and suggest that CFMs and/or their
future analogs have potential as anti-MPM agents.
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chemotherapy, and radiation [2]. Most chemotherapeutic agents
are not very effective against MPM, with typical single-agent
response rates of #20% [5]. The median survival of MPM
patients ranges from 9–17 months, and remains unacceptably low
[3]. Development of novel treatment strategies for MPM is
therefore warranted to improve the survival outcome in patients
and overcome resistance to currently available chemotherapies.
CARP-1, also known as CCAR1, is a peri-nuclear phosphoprotein that is a regulator of cancer cell growth and apoptosis
signaling [6–8]. In addition to being a key transcriptional coactivator of p53 in regulating adriamycin (ADR)-dependent DNA
damage-induced apoptosis, deprivation of serum growth factors also
resulted in elevated CARP-1 expression [6–8]. Antisense-mediated

Introduction
Malignant pleural mesothelioma (MPM) is a lethal asbestosrelated malignancy [1]. Scores of workers have been exposed to
asbestos throughout world. Since asbestos exposure has been
identified as a risk factor in diseases including asbestosis, lung
cancer and MPM [1], it is estimated that approximately 2,000–
3,000 people will be diagnosed as MPM patients each year in the
US. Although the use of asbestos has been significantly curtailed,
the incidence of asbestos-related diseases including MPM is
expected to continue in the next decade in the United States
and Europe [3,4]. The multimodality treatment for MPM in the
clinic often consists of surgery, adjuvant or neoadjuvant
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depletion of CARP-1, on the other hand, abrogated cancer cell
growth inhibition by ADR [6]. The apoptosis signaling by EGFRs
stimulated tyrosine phosphorylation of CARP-1 and targeted
CARP-1 tyrosine192, while CARP-1-dependent apoptosis in turn
involved activation of SAPK p38 and caspase-9 [8]. Recent studies
further revealed that protein kinase A (PKA) inhibitor H89
attenuates human breast cancer (HBC) cell growth in part by
targeting CARP-1 threonine667-dependent suppression of c-Myc
transcription [9]. Phosphopeptide mapping studies indicate that
CARP-1 is also a serine phospho-protein, and the epidermal growth
factor (EGF) as well as the ATM kinase signaling phosphorylates
specific serine residues of CARP-1 [10–12].
The Anaphase Promoting Complex/Cyclosome (APC/C) is a
multiprotein complex with E3 ubiquitin ligase activity [13].
Dysregulation of APC/C may be associated with tumorigenesis
since many APC/C-targeting/activating molecules such as
securin, polo-like kinase, aurora kinase, and SnoN are potential
oncogenes [14]. A yeast-two-hybrid (Y2H) screening assay
revealed CARP-1 interaction with APC-2 protein. Following
mapping of epitopes involved in CARP-1 binding with APC-2, we
developed a fluorescence polarization (FP) based in vitro binding
assay. High through-put screening of a chemical library in
conjunction with this FPA yielded multiple, small molecule
inhibitors (SMIs) of CARP-1/APC-2 binding, termed CARP-1
Functional Mimetics (CFMs) [15]. Here we investigated MPM
growth inhibition by CFMs. CFMs inhibit MPM cell growth in
part by stimulating apoptosis while impacting the motility and
invasion signaling and biological properties of colony formation,
invasion, and migration of the MPM cells. Our proof-of-concept
studies presented here show that pharmacologically-active CFMs
are suppressors of MPM cell growth, and suggest that CFMs or
their derivatives could provide novel means to combat/treat
resistant MPM.

Imgenex (San Diego, CA), respectively. Anti-Ubiquitin, Lys63Specific (Clone Apu3), and Anti-Ubiquitin, Lys48-Specific, (Clone
Apu2) rabbit monoclonal antibodies were obtained from Millipore,
Temecula, CA. Generation and characterization of the anti-CARP1/CCAR1 rabbit polyclonal antibodies have been described before
[6]. Enhanced Chemi-luminescence Reagent was purchased from
Amersham Biosciences (Piscataway, NJ) and the Protein Assay Kit
was purchased from Bio-Rad Laboratories (Hercules, CA).

Cell Lines and Cell Culture
Isolation, establishment and characterization of the human
MPM cell lines H2373, H2714, and H2461 has been described
before [16]. Murine mesothelioma AB12 cells were kindly
provided by Dr. Steven Albelda, University of Pennsylvania
Medical Center, Philadelphia, PA, and have been described before
[17]. Human MPM cells were routinely cultured in DMEM
supplemented with 10% FBS, 100 units/ml of penicillin, and
100 mg/ml of streptomycin. AB12 cells were cultured in highglucose DMEM supplemented with 10% fetal bovine serum,
100units/mL of penicillin, and 100 mg/mL of streptomycin. Cells
were maintained at 37uC and 5% CO2. For cell growth and
apoptosis studies, the MPM cells were cultured in fresh media with
5% FBS prior to their treatments with various agents.

Immuno-cytochemical labeling
For immuno-cytochemical analyses approximately 56103 cells
were seeded onto a slide well, and allowed to grow overnight at
37uC incubator. The cells were then either untreated, treated with
5 mg/ml Cisplatin, 20 mM CFM-1, 10 mM each of CFM-4 or
CFM-5 for 12 or 24 h. The slides were rinsed to remove the
media, and the cells fixed for staining using a 1:250 dilution of
anti-CARP-1 (a2) or anti-c-myc antibodies, or 1:500 dilution of
the anti-phospho-p38, DR5, or D2-40 antibodies. The antibodystained cells were then photographed under different magnifications utilizing Zeiss microscope with attached 35 mm camera for
recording the photomicrographs.

Methods
Materials
DMEM, Ham’s F-12 medium and fetal bovine serum (FBS) was
purchased from Life Technologies, Inc., Grand Island, NY. CFM-1,
4, and 5 were obtained from ChemDiv and/or ChemBridge, San
Diego, CA, and dissolved in dimethyl sulfoxide (DMSO) at a stock
concentration of 10, 50, and 50 mM, respectively, and stored at
220uC. Appropriate working concentrations were prepared with
the cell culture medium immediately before the experiments.
Cisplatin, DMSO, chemicals including 3–4, 5-dimethyltiazol-2-yl2.5-diphenyl-tetrazolium bromide (MTT), cremophor and anti bActin mouse monoclonal antibody were obtained from Sigma
Aldrich, St. Louis, MO. The monoclonal antibodies for ABIN2,
vimentin and c-myc, and the polyclonal antibodies for c-Jun, DR5,
and DR4 proteins were obtained from Santa Cruz Biotech, Santa
Cruz, CA. The mouse monoclonal antibody for a-tubulin and
phospho-serine monoclonal antibody 16B4 were obtained from
Calbiochem (Billerica, MA) and Enzo Life Sciences (Farmingdale,
NY), respectively. Anti-cyclin B1, anti-caspase-3, anti-phosphoJNK (Threonine183/Tyrosine 185) G9 mouse monoclonal antibodies, anti-JNK (56G8) rabbit monoclonal antibody, and rabbit
polyclonal antibodies for PARP, phospho and total p38 SAPK,
ABIN1, IkBa, and IkBb proteins were obtained from Cell Signaling
Technology (Beverly, MA). Anti-p21 Rac1 mouse monoclonal
antibody was purchased from BD Biosciences, San Jose, CA. Antipodoplanin D2-40 mouse monoclonal (SIG-3730; antigen M2A)
and rat monoclonal [Clone NZ-1.2; antigen: synthetic peptide
corresponding to amino acids 38–51 (EGGVAMPGAEDDVV) of
podoplanin] were purchased from Covance (Dedham, MA) and
PLOS ONE | www.plosone.org

Western Immuno-blotting, Immunoprecipitation, MTT
and apoptosis Assays
Logarithmically growing cells were treated with Cisplatin or
CFM compounds, and cells were lysed to prepare protein extracts.
For western immuno-blotting (WB) analyses, cells were harvested
and lysed in RIPA buffer (50 mM Tris-HCI, pH 8.0, 150 mM
sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), and 0.1% of protease inhibitor
cocktail) for 20 min at 4uC. The lysates were centrifuged at
14,000 rpm at 4uC for 15 min to remove debris. Protein
concentrations of whole cell lysates were determined using the
Protein Assay Kit. For immunoprecipitation, ,1 mg of proteins
from untreated or treated cell lysates were first incubated with
anti-phospho-serine monoclonal antibody 16B4 that specifically
recognizes phosphorylated serine residues that are immediately
followed by lysine (pSK, substrate for CDC kinase) or proline
(pSP, substrate for MAP/SAP kinases) essentially following
methods described before [8]. The protein extracts (50 or
100 mg) or immunoprecipitates were electrophoresed on 9–12%
SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membrane (Bio-rad, Hercules, CA) essentially as
described before [6,8]. The membranes were hybridized with
primary antibodies followed by incubation with appropriate
secondary antibodies. The antibody-bound proteins were visualized by treatment with the chemiluminescence detection reagent
(Amersham Biosciences) according to manufacturer’s instructions,
2
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fluorescence plate reader with 480/520 nm filter set. The
measurements were then plotted as bars in histogram.

followed by exposure to X-ray film (Kodak X-Omat). The same
membranes were re-probed with the anti-b actin or anti-a-tubulin
antibody, which was used as an internal control for protein
loading.
The cell growth inhibition was assessed by using MTT assay.
Briefly, a stock solution of 5 mg/ml of MTT was prepared in
sterile 16PBS, filtered through 0.2 mm filter, and stored at 2–8uC.
4–56102 cells were seeded in 96-well plates. After incubation with
or without agents, MTT stock solution equal to one tenth of the
original culture volume was added to each culture, followed by
incubation of cells at 37uC for further 2 h. At the end of the
incubation, the media was removed and cells were treated with
100–200 ml of DMSO to solubilize the dye. The assessment of the
live cells was derived by measuring the absorbance of the
converted dye at wavelengths of 490 to 570 nm.
Apoptosis levels were determined by staining for fragmented
DNA utilizing terminal deoxynucleotidyl transferase-mediated
nick end labeling (TUNEL) assay kit (Roche Diagnostics,
Indianapolis, IN) essentially following manufacturer suggested
protocols [6,8]. The cells were treated with various agents, fixed,
labeled and photographed essentially as detailed in immunocytochemical staining methods above.

Detection of MMP expression in human MPM cells
H2373 MPM cells were separately treated with CFM-4 or
CFM-5, followed by their homogenization in RIPA buffer (500 ml
of lysis buffer per 16106 cells). The cell lysates were centrifuged at
10,0006 g for 5 min, and the protein concentration in the
supernatant of the respective lysate was determined by using
Bicinchoninic acid assay. The lysates were stored at 280uC until
further use. MMP activation in each lysate was measured using the
Quantibody reverse phase human MMP array kit according to
manufacturer’s instructions (RayBiotech, Norcross, GA). Fluorescence images were detected using a GenePix 4100A Scanner, and
data was analyzed using the QAH-MMP-1 GAL software based
on the instruction provided by the array manufacturer.

Statistical analysis
Where appropriate, statistical analysis was performed using
unpaired Student’s t-test. A p value less than 0.05 between
treatment groups was considered significantly different.

Results

Cell Migration, Invasion, and Clonogenic Assays

CFMs inhibit MPM cell proliferation in part by stimulating
apoptosis

The effects of CFMs on migration of MPM cells were measured
by the ‘‘scratch’’ assay. Cells were grown in a 6-well plate
(,10,000 cells/well), and a scratch was created in the cell
monolayer using sterile pipette tip. The cells were then allowed to
grow in the absence (Control) or presence of 10 mM dose of each
of the CFMs for a period of 72–96 h. Images were captured at the
beginning and at regular intervals during cell migration to close
the scratch, and the images were compared to quantify the
migration rate of the cells essentially as described before [18]. The
cells were photographed under different magnifications utilizing
Zeiss microscope with attached 35 mm camera for recording the
photomicrographs.
Clonogenic assay: Cells were sandwiched between 0.6% and
0.3% agarose in DMEM medium containing 5% FBS in a six-well
chamber (500 cells/chamber), and treated with buffer (Control), or
respective CFM (10 mM) for 9 days at 37uC humidified CO2
incubator. The colonies from multiple random fields were
counted, compared to control and photographed essentially as
above.
Invasion assay: Basement membrane is a thin extracellular
matrix (ECM) that underlies epithelia and endothelia and
separates epithelial cancer cells from the stroma. Tumor cells
produce proteases that degrade ECM to cross the basement
membrane to invade stroma and establish distant metastases. The
in vitro Boyden Chamber assay (Chemicon International, CA)
using Matrigel is the most reliable, reproducible, and representative of in vivo invasion. In this assay, cancer cells are placed in the
upper chamber that is separated from the lower chamber by a
porous membrane coated with Matrigel [18,19]. Briefly, prewarmed serum free medium (300 ml) was used to hydrate the
ECM layer of each chamber for 15–30 minutes at room
temperature. Approximately 2–2.56105 MPM cells were seeded
in the upper chamber in a serum-free medium without or with
10 mM dose of the respective CFM. The lower chamber was
supplied with medium containing 10% FBS that served as chemoattractant to stimulate migration. After an interval, tumor cells
present on the lower side of the membrane in the lower chamber
were stained, and photographed as above. In addition, the stained
cells from the lower side of membrane of some wells were
dissociated, lysed in a buffer, followed by quantitation using a
PLOS ONE | www.plosone.org

We have previously found that viabilities of a number of MPM
cells were affected following their treatments with CFM-1, -4, or -5
[15]. A majority (,60–70%) of MPM are characterized as
epithelioid histotype. Additional histotypes include sarcomatoid
(10–15%) and biphasic/mixed (10–15%) MPM, and are generally
more aggressive tumors with poor outcomes. Since Cisplatin is
often used as a frontline therapy for MPM in clinic, here we
utilized H2461 (epithelioid histologic origin) and H2373 (sarcomatoid histologic origin) MPM cells [16] in a proof-of-concept
study to further investigate anti-MPM efficacies of CFMs, and to
determine whether CFMs are superior to Cisplatin in inhibiting
MPM cell growth. As expected, CFM-1, 4, 5, or Cisplatin
inhibited the viability of both the cell lines in a time-dependent
manner (Figure 1). In general, the cells were more sensitive to
inhibition by all the CFMs when compared with Cisplatin. A
20 mM dose of CFM-1 for 24 h period resulted in approximately
50% growth inhibition of both the MPM cells (Figure 1A). A
20 mM dose of CFM-4 or CFM-5 over a 24 h treatment elicited
,90% loss of viabilities of both the MPM cells (Figure 1A).
Cisplatin treatments (5 mg/ml) over 24 h and 48 h periods
however resulted in a modest 10–20% and 50% loss of MPM
cell viability, respectively (Figure 1A, B). MPM cells treated with a
combination of Cisplatin and either of the CFMs failed to elicit a
higher level of growth inhibition. We next investigated whether
CFMs promoted apoptosis to inhibit MPM cell growth. Given that
a 24 h treatment of both the MPM cells with 20 mM dose of
respective CFM resulted in a significant, 50–90-% loss of their
viabilities, we chose to utilize a 20 mM dose of each compound to
determine induction of apoptosis and the underlying molecular
mechanism(s). For immunocytochemical analyses, the MPM cells
were directly cultured in 8-well chamber slides and were either
untreated or treated with respective CFMs, chemotherapeutic
agents Adriamycin (ADR; 2.5 mg/ml) and Cisplatin (5 mg/ml) for
a period of 24 h as detailed in Methods. Treatment of the MPM
cells with each of the agents resulted in elevated number of
TUNEL-positive cells (Figure 2A, B). Additional WB analysis
revealed elevated cleavage of caspase-target poly(ADP-ribose)
polymerase (PARP) following 24 h treatment of H2461 MPM
3
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cells. Although exposure to Cisplatin or CFMs caused reduced
levels of PARP1 protein, treatments with the 20 mM dose of CFM4 or CFM-5 however resulted in a robust cleavage of PARP-1 in
the MPM cells (Figure 2C, D). We have previously found that
activation of caspases was necessary for transduction of CFM-4dependent growth inhibitory signaling in HBC cells [15]. Since
CFMs promoted PARP cleavage in MPM cells (Figure 2C), we
next determined whether caspases were activated following
exposure of the MPM cells to CFMs. As shown in figure 2D,
treatment of the MPM cells with CFM-4 resulted in elevated levels
of cleaved (activated) caspase-3. The data in figures 1 and 2
therefore suggest that CFMs are novel and superior inhibitors of
MPM cell growth when compared with conventional anti-MPM
therapeutic Cisplatin, and all the three CFMs attenuate MPM cell
growth in part by stimulating apoptosis.

elevated CARP-1 levels following treatments with these agents,
WB analysis of the lysates derived from Cisplatin, CFM-1, CFM-4,
or CFM-5-treated MPM cells revealed a robust increase in CARP1 expression when compared with its levels in the lysates from the
untreated control cells (Figure 3C, D). However, increase in
CARP-1 levels in the cells treated with Cisplatin in combination
with either of the CFMs was not significantly different than that
noted in the case of the cells treated with each agent alone.
Together with data in figure 1 where Cisplatin in combination
with CFMs failed to cause increased growth inhibition of MPM
cells when compared with either agent alone, the data suggest for a
likely overlap of the molecular mechanisms of MPM growth
suppression by Cisplatin and CFMs.
Our previous studies have noted a requirement for p38 SAPK
in CARP-1-dependent apoptosis signaling [8]. Moreover, our
recent reports have revealed that CFM-4 that binds with CARP-1,
promoted apoptosis in part by increasing CARP-1 levels and p38
activation in a number of cancer cells including the HBC and
medulloblastomas [15,20]. Here we tested the extent MPM cell
inhibitory signaling by CFMs involved activation of SAPKs. We
first determined whether and to what extent CFMs can stimulate
p38 activation in the MPM cells. Immuno-cytochemical and WB
analyses were performed to determine CFM-mediated changes in
p38 activation. Treatments with CFM-1, -4, or -5 resulted in
elevated staining for phosphorylated (activated) p38 in H2373 cells
(Figure 4A) when compared with their untreated counterparts.
WB analysis of the cell lysates corroborated a robust activation of
p38 in CFM-4, or CFM-5-treated H2461 (Figure 4B) and H2373
(Figure 4C) MPM cells when compared with their untreated
controls. Further, WB analysis of the cell lysates revealed
activation of JNK1/2 SAPK in the CFM-4-treated MPM cells
while treatments of MPM cells with Cisplatin, CFM-1 or CFM-5
did not activate JNK1/2 (Figure 4D, E). These data indicate that
although all the CFMs inhibit MPM cell growth in part by
stimulating apoptosis, the molecular mechanisms of apoptosis

Apoptosis signaling by CFMs involves activation of
pro-apoptotic stress-activated protein kinases (SAPKs),
and elevated expression of a novel transducer of
apoptosis CARP-1/CCAR1
CARP-1/CCAR1 has been previously reported by our laboratory and others as a novel and biphasic transducer of cell growth
and apoptosis signaling. While CARP-1 functions as a co-activator
of nuclear, steroid/thyroid transcription factors, it also functions as
a key regulator of p53 function and a transducer of apoptosis
signaling by DNA damaging agents such as ADR [6,7]. Since both
the MPM cells displayed increased sensitivity to inhibition by
CFM-4 and CFM-5, we next determined whether treatments of
MPM cells to these compounds altered CARP-1 expression. In the
first instance, the H2373 and H2461 cells were either untreated or
treated with ADR, Cisplatin, CFM-1, CFM-4, or CFM-5 as in
figure 2, and CARP-1 levels were analyzed by immunocytochemical staining utilizing anti-CARP-1 a2 antibodies as
noted in Methods. Exposure to CFMs or the chemotherapeutic
agents ADR and Cisplatin resulted in increased staining for
CARP-1 in both the MPM cells (Figure 3A, B). Consistent with

Figure 1. CFMs reduce viabilities of the human MPM cells. Cells were treated with vehicle (Untreated Control), indicated doses of Cisplatin,
various CFMs, or a combination of Cisplatin and CFMs for 24 h (A) or 48 h (B). Determination of viable/live cells was carried out by MTT assay. The
data in the histograms represent means of three independent experiments; bars, S.E. * and #, p = ,0.05 relative to Untreated Control (A). Note that
the Y-axis scale is different in panel B.
doi:10.1371/journal.pone.0089146.g001

PLOS ONE | www.plosone.org
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Figure 2. CFMs stimulate apoptosis in MPM cells. (A, B) Indicated MPM cells were either untreated (Control), treated with 2.5 mg/ml Adriamycin,
5 mg/ml Cisplatin or 20 mM dose of respective CFMs for 24 h. Staining of the cells was performed using TUNEL assay as detailed in Methods. Dark
brown staining represents fragmented cell nuclei. (C, D) MPM cells were either untreated (denoted as Control in panel C and – in panel D) or treated
(denoted as+in panel D) with indicated agents for noted time and dose, and levels of cleaved PARP, pro- and cleaved (activated) caspase-3, and actin
proteins were determined by Western blotting.
doi:10.1371/journal.pone.0089146.g002

signaling by CFM-4 are likely distinct from that of the CFM-1,
CFM-5 or Cisplatin.
Our earlier studies have also indicated that in addition to
stimulating CARP-1 levels and SAPK activation, CFM-4 treatments induced loss of a number of key cell cycle and cell growth
regulatory molecules. In particular, levels of mitotic cyclin B1, cell
growth and motility regulatory small GTP-binding protein
p21Rac1, and oncogene c-myc were diminished in CFM-4-treated
cells [15]. In light of these observations, we further investigated
whether treatments of MPM cells with CFMs also results in loss of
cyclin B1, p21Rac1, and c-myc proteins. As shown in figure 5A,
reduced immuno-cytochemical staining for c-myc was noted in
H2461 MPM cells that were treated with ADR or CFMs.
Consistent with these findings, reduced levels of oncogenes c-jun
and c-myc were noted in the lysates of CFM-4-treated human and
murine MPM cells by WB analysis (Figure 5B). Additional WB
analysis further supported down-regulation of c-myc in MPM cells
that were treated with CFMs, but not Cisplatin (Figure 5C). CFM1, CFM-4 or CFM-5 treatments also suppressed expression of
cyclin B1 and p21Rac1 proteins in MPM cells (Figure 5C, D).

PLOS ONE | www.plosone.org

CFMs activate NF-kB signaling in MPM cells
The NF-kB family of proteins and their signaling is well known
to play a crucial role in organismal physiology and pathologies
such as chronic inflammation and cancer. Activation of proapoptotic MAPKs (p38 or JNK) on the other hand serves to
attenuate NF-kB activation in different stress-induced apoptotic
contexts [21,22]. A number of recent studies have revealed a proapoptotic role for NF-kB signaling [23–25], and together with our
recent observations indicating that prolonged exposure of medulloblastoma cells to CFM-4 also resulted in NF-kB activation that
likely serves to potentiate/support apoptosis [20]; we investigated
the extent CFMs also regulated NF-kB signaling in MPM cells.
Our data in figure 6 show that treatments of MPM cells with
CFM-1, CFM-4, or CFM-5 results in a diminished levels of NF-kB
inhibitory IkBa and/or IkBb proteins suggesting that these
compounds likely activate NF-kB in MPM cells. However,
Cisplatin treatments of MPM cells failed to diminish expression
of NF-kB inhibitory IkBa and/or IkBb proteins (Figure 6A, B).
A range of extrinsic and intrinsic signals regulate cell growth
and survival by modulating canonical NF-kB signaling [26]. In the
canonical pathway, levels of NF-kB inhibitory IkBa and/or IkBb
proteins are regulated by upstream kinase IKK that itself is subject
5
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Figure 3. CFMs enhance expression of pro-apoptotic CARP-1. (A, B) Indicated MPM cells were either untreated (Control), treated with
Adriamycin, Cisplatin, or respective CFMs as in figure 2. Staining of the cells was performed using anti-CARP-1 (a2) antibody as detailed in Methods.
Presence of CARP-1 is indicated by intense brown staining in the nuclei and cytosol of the treated cells. (C, D) MPM cells were either untreated
(Control) or treated with different agents for indicated dose and time, and cell lysates were analyzed by western blotting for levels of CARP-1 and
actin proteins as in Methods.
doi:10.1371/journal.pone.0089146.g003

to control by inhibitory molecules such as ABIN1 and 2 proteins
[27,28]. Although ABIN2 levels were significantly up-regulated in
CFM-treated H2373 cells, CFM-4 or CFM-5 treatments promoted loss of ABIN2 expression in H2461 cells (Figure 6A, B). ABIN1
expression however was consistently down-regulated in both the
MPM cells following their treatments with each of the CFMs
(Figure 6). It is also of note here that Cisplatin treatments failed to
alter levels of either of the ABIN1, or ABIN2 proteins.
The tumor necrosis factor (TNF) family of cytokines that
include TNF-related apoptosis-inducing ligand (Apo2L/TRAIL)
regulate apoptosis by binding to five TNF receptor superfamily
members [29]. TRAIL binding to the death receptor 4 (DR4,
TRAIL-R1, TR1) and death receptor 5 (DR5, TRAIL-R2, TR2)
activates apoptosis signals through the cytoplasmic death domains
of the DR4 and 5 receptors. Three additional TRAIL receptors,
decoy receptor 1 (DcR1), decoy receptor 2 (DcR2), and soluble
osteoprotegerin (OPG), lack the ability to initiate apoptosis and
function as inhibitory receptors [30–33]. Activation of apoptosis
signaling by DRs remains an attractive strategy for therapeutic
applications since recombinant human (rh)Apo2L/TRAIL and
agonistic antibodies directed against either DR4 or DR5 have
shown activity in vitro and in vivo against a range of cancers, and
combinations of DR agonists with conventional chemotherapeutics have shown promise in preclinical testing [34–37]. Although a
PLOS ONE | www.plosone.org

variety of normal and cancer cells express DR4 and DR5, and
TRAIL has been shown to activate apoptosis signaling in cancer
cells, it is likely that elevated levels of DR4 and/or DR5 could
sensitize cancer cells to apoptosis by chemotherapy alone or in
combination with DR agonists. Since caspase-8 activation is an
early and key requirement for apoptosis following DR activation
[38], and the fact that caspase-8 activation was also required for
apoptosis by CFM-4 in HBC cells [15], we investigated whether
MPM cell growth suppression by CFMs involved DRs. Immunocytochemical analysis revealed increased staining for the DR5
protein in MPM cells that were treated with Cisplatin, CFM-1 or
CFM-5 (figure 7A, B). The western immunoblot analysis
(figure 7C, D) further confirmed elevated expression of DR4 and
DR5 proteins in Cisplatin or CFM-treated MPM cells. To the
extent, elevated levels of DR4 and DR5 contributed to anti-MPM
effects of CFMs remain to be clarified. However, activation of proapoptotic p38, and elevated levels of CARP-1, DR4, and DR5
proteins indicates for an overlap of the MPM growth inhibitory
molecular mechanisms utilized by Cisplatin and CFMs. The fact
that CFM-4 also activates pro-apoptotic JNK1/2 and NF-kB
(Figures 4, 6), and suppress levels of p21Rac1, c-myc and cyclin B1
proteins (figure 5), would suggest that CFM-4 utilizes additional
MPM inhibitory molecular mechanisms that are distinct from
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Figure 4. CFMs activate pro-apoptotic SAPKs in MPM cells. (A, B) Indicated MPM cells were either untreated (Control), treated with
Adriamycin, Cisplatin, or respective CFMs as in figure 2A. Staining of the cells was performed using anti-phospho-p38 antibody as detailed in
Methods. Presence of p38 is indicated by intense brown staining in the nuclei and cytosol of the treated cells. MPM cells were either untreated
(Control) or treated with indicated agents for noted time and dose, and levels of phosphorylated p38 (noted as p-p38), and total p38 proteins (B, C) or
phosphorylated JNK (noted as p-JNK1/2), and total JNK proteins (D, E) were determined by Western blotting essentially as in figure 2.
doi:10.1371/journal.pone.0089146.g004
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Figure 5. CFMs suppress expression of transducers of MPM cell growth and survival. (A–C) CFM treatments result in loss of c-myc in MPM
cells. In panel A, cells were either untreated (Control), treated with Adriamycin, Cisplatin, or respective CFMs as in figure 2A, followed by staining of
cells using anti-c-myc antibody as detailed in Methods. Presence of c-myc is indicated by intense brown staining in the nuclei of the untreated cells.
(B–D) MPM cells were either untreated (denoted as Control in panels C and D, and – in panel B) or treated (denoted as+in panel B) with indicated
agents for noted time and dose, and cell lysates were analyzed by western blotting for levels of c-Jun (panel B), c-myc (panels Band C), and cyclin B1
(panels C and D) and actin proteins as in Methods.
doi:10.1371/journal.pone.0089146.g005

strategies that target podoplanin or vimentin [49–51], we next
determined whether CFMs modulated expression of podoplanin
and vimentin proteins in the MPM cells.
Immunocytochemical analysis of MPM cells treated with CFM1, CFM-4, or CFM-5 in conjunction with D2-40 anti-podoplanin
antibody revealed higher levels of podoplanin when compared
with their untreated or Cisplatin-treated counterparts (figure 8A).
Consistent with the immunocytochemical analysis, western blot
data failed to show elevated levels of podoplanin peptides in
Cisplatin-treated cells (Figure 8B, C). MPM cells that were treated
with CFMs, in particular CFM-4 or CFM-5, however, revealed a
robust increase in podoplanin peptides of 75 kDa and higher sizes
(Figure 8B, C). Because of the extensive post-translational
modifications such as glycosylation, the podoplanin is often
expressed as peptides of 50 kDa or higher molecular weights
whereas its cDNA encodes for a peptide of 162 aminoacids with an
expected molecular mass of ,18–20 kDa. To confirm whether
CFM-4 treatments induced expression of the 75 kDa and higher
sized podoplanin peptides, we conducted additional western blot
analysis of lysates from the CFM-1 or CFM-4-treated MPM cells
utilizing a second anti-podoplanin rat monoclonal antibody NZ1.2. Although CFM-4-treatment caused a modest increase in levels

those activated by Cisplatin that could be responsible for its
superior anti-MPM efficacies noted in figure 1.

CFM-4 inhibits MPM cell motility, migration, colony
formation, and invasion
We next investigated whether CFMs inhibit biological properties of migration, invasion and colony formation by the MPM cells,
and the molecular mechanisms involved. A variety of cell surface
and intracellular proteins in conjunction with factors in the
extracellular matrix regulate motility and invasive properties of the
cancer cells. A number of studies have revealed that a sialomucin
type I transmembrane glycoprotein, podoplanin, regulates processes of cell migration, epithelial-to-mesenchymal transition
(EMT), and tumor metastasis, as well as cell cycle and cell
proliferation through extracellular matrix signaling, and is often
related to tumor malignancy and poor outcome in many cancers
including MPM [39–44]. In addition to podoplanin, a type III
intermediate filament cytoskeletal protein, vimentin, that regulates
cytoskeletal interactions such as adhesion, migration and signaling,
is also frequently overexpressed in invasive cancer cells and
associates with metastasis and poor prognosis [45–48]. In light of
the recent reports that have highlighted anti-MPM intervention
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Figure 6. CFM-4 but not Cisplatin activates canonical NF-kB signaling. H2373 (A) and H2461 (B) MPM cells were either untreated (Control) or
treated with noted agents for indicated dose and time, and cell lysates were analyzed by western blotting for levels of ABIN1, ABIN2, IkBa, IkBb, and
actin proteins as indicated in Methods.
doi:10.1371/journal.pone.0089146.g006

we next clarified whether the cytoplasmic region of podoplanin
was also ubiquitinated following its serine phosphorylation in the
presence of CFM-4. Many cellular proteins are well known to be
ubiquitinated on the lysine residues following phosphorylation of
the neighboring serine and/or threonine residues. Lysine48-linked
ubiquitination of proteins often serves as a signal for their
proteasomal degradation while lysine63-linked ubiquitination is
associated with non-proteolytic functions such as signal transduction [13, 53, and 54]. Western blot analysis of immunoprecipitated, lysine63-linked proteins revealed presence of a ,75 kDa
podoplanin in lysates derived from MPM cells that were treated
with CFM-1 or CFM-4 (figure 8D). Similar western blot analysis of
immunoprecipitated, lysine48-linked proteins failed to indicate
presence of podoplanin (not shown). Together, these data suggest
that lysine63-linked ubiquitination is involved in increased
podoplanin expression following CFM-4 treatments, while the
phosphorylated podoplanin, in turn, is inhibited to signal for
cellular motility and invasion processes. In addition, western
immunoblot analysis of cisplatin or CFM-treated MPM cells
showed robust cleavage of vimentin when compared with their
untreated counterparts (figure 8B, C). Collectively, the data in
figure 8 suggest that CFM-4 treatments likely impact cellular
motility and invasion-associated functions of podoplanin and
vimentin proteins in the MPM cells.
We further clarified the extent CFMs affect the biological
properties of the MPM cells by performing wound-healing, soft-

of the 50 kDa podoplanin peptide in the lysates analyzed with NZ1.2 antibody, both the NZ-1.2 and D2-40 monoclonal antibodies
showed a robust increase in a 75 kDa peptide in the CFM-4treated cells (supplementary figure 1). These data strongly suggest
that CFM-4 stimulates expression of a 75 kDa-sized podoplanin
peptide in MPM cells. Given that podoplanin expression is often
associated with cancer cell motility, migration and invasion, a
recent report demonstrated that PKA phosphorylation of serines
in the intracellular tail of podoplanin infact interfered with the
ability of podoplanin to regulate cell motility and migration [52].
Since CFM-4 activated p38 and JNK SAPKs (figure 4), and
SAPKs are proline-directed serine/threonine kinases that phosphorylate serine or threonines that are followed by proline amino
acid in their substrates, and the fact that podoplanin proteins of
human, mouse and rat origins all have a conserved C-terminal
serine that is followed by proline, it is likely that stress signaling
induced by CFM-4 not only enhances podoplanin expression but
also its serine phosphorylation to attenuate podoplanin-dependent
motility and invasion signaling. Western blot analysis of immunoprecipitated, serine phosphorylated proteins revealed robust serine
phosphorylation of podoplanin peptides in CFM-4-treated MPM
cells while a modest podoplanin phosphorylation was also noted in
the CFM-1-treated cells (figure 8D) when compared with their
untreated counterparts. Given that there is a conserved lysine
residue within the short cytoplasmic domain of podoplanin
proteins of human, rat, and murine origins (VVMxKxSGRxSP),
PLOS ONE | www.plosone.org
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Figure 7. CFMs stimulate expression of cell death signaling death receptors (DRs) 4 and 5 in MPM cells. (A, B) Indicated MPM cells were
either untreated (Control), treated with Cisplatin, or respective CFMs as in figure 2A. Staining of the cells was performed using anti-DR5 antibody as
detailed in Methods. Presence of increased DR5 is indicated by intense brown staining in the cytosol of the treated cells. MPM cells were either
untreated (Control) or treated with indicated agents for noted time and dose, and levels of DR4, DR5 and actin proteins (C, D) were determined by
Western blotting essentially as in figure 2.
doi:10.1371/journal.pone.0089146.g007

purpose we conducted an antibody-based array analysis to
determine activation status of various MMPs in control (untreated)
versus treated H2373 MPM cells as indicated in Methods. These
data revealed that exposure of MPM cells to CFM-4 or CFM-5
resulted in attenuation of MMP-1, -8, and -9 activities (Figure 9B).
Whether CFM-dependent attenuation of MMP activities interfered with invasive properties of the MPM cells was determined
next by testing the extent to which CFMs blocked the ability of
MPM cells to invade through the matrigel-coated membranes. As
expected, treatment of MPM cells with CFM-4 resulted in a
significantly reduced number of cells that were able to migrate
across the matrigel-coated membranes (Figure 9C). Taken
together, these data show that CFMs, in particular CFM-4, have
the ability to interfere with MPM cell invasion and metastasisinducing pathways.

agar, and matrigel-invasion assays, respectively, as detailed in
Methods. Since 20 mM dose of CFM-4 and -5 caused extensive
apoptotic cell death (see figures 1 and 2), and the fact that the
wound healing, soft-agar colony formation, and invasion assays
were performed over the treatment periods longer than 24 h, we
utilized a lower, 10 mM dose of each CFM to minimize
interference from apoptosis in these assays. Presence of CFM-4
or -5 prevented the H2373 MPM cells from growing in the areas
of wound created by a scratch, and also caused a greatly reduced
number and size of their colonies in soft agar when compared with
their respective, untreated controls (Figure 9A). Since cellular
motility and invasive processes are often also regulated by extrinsic
factors in the extra-cellular matrix, and various matrix metalloproteinases (MMPs) are often activated in invasive cancers and
contribute to poor prognoses, we determined whether exposure to
CFMs also diminished activities of any of the MMPs. For this
PLOS ONE | www.plosone.org
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Figure 8. CFM-4 elevates expression and serine phosphorylation of podoplanin. (A) Indicated MPM cells were either untreated (Control),
treated with Cisplatin, or respective CFMs as in figure 2A. Staining of the cells was performed using anti-podoplanin D2-40 antibody as detailed in
Methods. Presence of increased podoplanin is indicated by intense brown staining in the cytosol of the CFM-1, CFM-5, and CFM-4-treated cells. MPM
cells were either untreated (Control) or treated with indicated agents for noted time and dose, and levels of podoplanin, vimentin, actin and a-tubulin
proteins (B, C) were determined by Western blotting essentially as in figure 2. (D) H2373 cells were either untreated (Control) or treated with agents
as indicated. The cell lysates (1 mg of protein) were first subjected to immunoprecipitation using anti-phospho-serine, anti-Ubiquitin (lys48-specific),
or anti-Ubiquitin (lys63-specific) antibodies as in methods. The membranes with cell lysates (50 mg/lane; blot on the left) or the immunoprecipitates
(blot on the right) were probed with anti-podoplanin D2-40 antibody as in panel C.
doi:10.1371/journal.pone.0089146.g008

the levels of key cell cycle regulatory proteins such as cyclin B1 and
c-myc. In addition to stimulating CARP-1 expression and
activation of pro-apoptotic SAPKs (p38 and JNK), we report for
the first time that CFM-4 caused elevated levels of phosphorylated
podoplanin, while down-regulating key transducers of invasion
and metastasis pathways.
Post-translational modifications such as phosphorylation, acetylation, ubiquitination, and glycosylation of the proteins that are
involved in transduction of cellular growth and survival signaling
often play critical roles in processes of cell growth, survival and
homeostasis. Although kinases such as SAPKs are activated by
phosphorylation of specific amino-acids in their catalytic domain,
the phosphorylation of their substrates often serves to amplify or
attenuate signaling in a context-dependent manner. Expression of
a number of signaling proteins is often regulated also by their
ubiquitination that follows their phosphorylation. In general, the
proteins that are ubiquitinated at lysine (K)63 positions are
stabilized for signaling while those that undergo ubiquitination at

Discussion
The management of MPM in the clinic remains challenging due
primarily to the lack of sufficient treatment options. The front-line
therapeutic strategies include multi-targeted antifolate agent,
pemetrexed, in combination with cisplatin, the overall prognosis
of patients with MPM still remains poor. Recent studies have
focused on development of small molecule or antibody-based antiMPM approaches [49,51], there however remains a pressing need
for development and testing of new anti-MPM modalities. The
studies presented here highlight anti-MPM potential of a novel
class of compounds termed CFMs that we have recently identified
and characterized. CFMs, in particular CFM-4, are cytotoxic
toward a wide variety of cancer cells as well as their drug-resistant
counterparts but do not inhibit non-tumorigenic mammary
epithelial MCF-10A cells [15]. Consistent with these observations,
our current studies demonstrate that CFM-4 suppressed MPM cell
growth by activating apoptosis signaling as well as by diminishing
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Figure 9. CFMs inhibit MPM Cell Growth in Soft Agar, invasion and MMP activities. (A) MPM cells were either untreated (Control) or
treated with indicated dose of respective CFMs, and were subjected to the subjected to the scratch assays (indicated as wound healing assay; upper
panel) or soft-agar assay (lower panel). The cells in the scratch assay or the colonies of cells in soft-agar were photographed as described in Methods.
Representative photomicrographs of untreated and CFM-treated H2373 cells are shown. (B) The H2373 cells were either untreated [Control (DMSO)]
or treated with CFM-4 or CFM-5 for noted dose and time. Cell lysates were analyzed for activities of various MMPs as detailed in Methods. The data in
the histogram represents means of the activities of the noted MMPs from three independent experiments; bars, S.E. (*, %, and &, p = ,0.05 relative to
respective MMP activities in Control cells). (C) The MPM cells were separately seeded in chambers with matrigel-coated membranes, and treated with
buffer (Control) or with 10 mM dose of respective CFMs as noted in Methods. Live cells migrating across the matrigel-coated membranes were
dissociated, and quantitated by an MTT-based assay. The columns in histogram represent MTT OD of the CFM-treated MPM cells relative to untreated
controls. (*, p = ,0.02 relative to buffer-treated (Control) cells).
doi:10.1371/journal.pone.0089146.g009

signaling for cellular motility while ubiquitination-dependent
stabilization would further amplify MPM motility inhibitory
properties of phosphorylated podoplanin in the presence of
CFM-4.
Ability of CFMs, particularly CFM-4, to inhibit MPM cell
migration and invasion is consistent with their recently demonstrated effects on the motility and migration of the medulloblastoma (MB) cells [20]. Signaling by extracellular matrix MMPs, cell
surface sialoglycoprotein podoplanin, intracellular small GTPbinding p21Rac1, and vimentin proteins are well known to
regulate processes of cellular motility, migration and invasion of
cancer cells. Moreover, deregulated expression and/or activation
of MMPs, podoplanin, p21Rac1, and/or vimentin are often
associated with poor prognosis in many cancers [41–49]. The fact
that CFM-4 exposure diminished activities of a number of MMPs,

the K48 position are degraded by the proteasome system [13,53].
Although, CFM-4 stimulated serine phosphorylation and lysine63linked ubiquitination of podoplanin, and the fact that both the
anti-podoplanin antibodies are expected to recognize a 40–43 kDa
O-linked sialoglycoprotein, and since each ubiquitin subunit is
,8–9 kDa size, it likely that conjugation of three or more
ubiquitin subunits resulted in a 75 kDa and higher molecular
weight podoplanin proteins in the CFM-4-treated MPM cells.
Moreover, since CFM-4 prevents CARP-1 binding with APC-2
and inhibits function of APC/C E3 ubiquitin ligase [15], and
APC/C ligase is well known to inversely regulate activity of SCF
ubiquitin ligase [13,14], it is possible that SCF ligase or another
similar E3 ligase that is a target of APC/C, ubiquitinates serinephosphorylated podoplanin. If so, the phosphorylation of podoplanin will likely serve a dual purpose by interfering with its
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caused vimentin cleavage and suppressed p21Rac1 levels while
phosphorylating and likely disabling podoplanin-dependent motility signaling in MPM cells would underscore invasion and
motility inhibitory properties of this class of compounds. On the
basis of our earlier findings indicating robust apoptosis induction
in cancer cells by CFM-4 [15], and the fact that Cisplatin
treatments failed to alter expression of p21Rac1 or podoplanin in
MPM cells (figures 5, 8) coupled with our data demonstrating
inhibition of a diverse metastasis signaling by CFM-4 would argue
for its pleiotropic anti-cancer properties, and collectively indicate
for potential of CFM-4 and/or its futuristic analogs as suitable
anti-MPM agents.
Our current and recent observations [20] revealed that CFM-4
activated p38 and JNK SAPKs as well as signaling by NF-kB. A
large body of literature has thus far established that context and
signal-dependent activation of p38 and/or JNKs could result in
cell survival or apoptosis outcomes [55]. NF-kB however has been
widely recognized as a highly versatile signaling transcription
factor involved in regulation of cell growth, survival, and
metastasis processes. Recent studies have further highlighted a
crucial role for NF-kB in determining the outcome of the DNA
damage response of the cells [56,57]. NF-kB signaling was found
to promote cell survival in the presence of a low to moderate levels
of DNA damage while extensive DNA damage provoked TNFamediated JNK3-dependent apoptosis. A number of recent
publications have further suggested possibility of NF-kB signaling
in promoting apoptosis [23–25]. The nuclear to cytoplasmic
signaling by NF-kB essential modulator (NEMO/IKKc) plays a
critical role in activation of canonical NF-kB pathway following
DNA damage. Since CFM-4 caused diminished levels of ABIN1
(A20 binding inhibitor of NF-kB; aka TNIP1) in both the MPM
(figure 6) and MB cells [20], it conceivable that loss of ABIN1
facilitates formation and/or activation of the IKK. The active
IKK in turn targets IkBs to promote NF-kB nuclear translocation
and transcriptional activation of its target genes. Together with the
facts that CFM-4 exposure of the MPM (figure 6) and MB cells
[20] also resulted in loss of IkBs would suggest that the canonical
NF-kB pathway was activated by this agent. Whether activation of
p38, JNK1/2, and/or NF-kB by CFM-4 play a role in apoptosis of
MPM cells or function as defensive mechanisms to ensure MPM

cell survival and recovery from CFM-4 treatments, and to the
extent CFM-4 exposure also caused damage to the cellular DNA
remain to be clarified. Nevertheless, CFM-4 was more effective in
inhibiting growth of MPM cells when compared with Cisplatin
(figure 1), and although both the agents suppressed MPM growth
by promoting apoptosis, it is likely that activation of JNK1/2 as
well as NF-kB pathways, coupled with loss of cyclin B1, c-myc,
and p21Rac1, and phosphorylation of podoplanin contribute to
the superior anti-MPM effects of CFM-4.
In summary, the data presented here support our working
hypothesis that CFMs activate multiple cell growth inhibitory and
apoptosis pathways to suppress MPM cell growth, survival and
metastasis processes, and underscore their potential as novel class
of anti-MPM agents.

Supporting Information
Figure S1 Podoplanin expression in H2373 MPM cells.
MPM cells were either untreated (Control), treated with CFM-1 or
CFM-4 for noted dose and time. Two sets of cell lysates (50 mg
protein/lane) were electrophoresed on 10% SDS-PAGE gel and
proteins transferred to nitrocellulose membrane as in methods.
The membrane containing one set of protein lysates was probed
with anti-podoplanin antibody NZ-1.2 (autoradiogram on the left)
and the membrane containing the second set of lysates was probed
with anti-podoplanin D2-40 antibody (autoradiogram on the
right). Both the membranes were then probed with anti-actin
antibody to assess loading.
(TIF)
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